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Abstract
We evaluated the ability of the combination disk test (CDT) and
the Modiﬁed Hodge Test (MHT) to discriminate between vari-
ous carbapenemase-producing Pseudomonas aeruginosa isolates
(KPC, n = 36; metallo-b-lactamase (MBL), n = 38) and carbape-
nemase non-producers (n = 75). For the CDT, the optimal
inhibitor concentrations and cut-off values were: 600 lg of
3-aminophenylboronic acid (APB) per disk (an increment of
‡4 mm), 1000 lg of dipicolinic acid (DPA) per disk (an incre-
ment of ‡5 mm) and 3000 lg of cloxacillin per disk (an incre-
ment of ‡3 mm). APB had excellent sensitivity (97%) and
speciﬁcity (97%) for the detection of KPC enzymes. DPA
detected MBL enzymes with a sensitivity and speciﬁcity of 97%
and 81%, respectively. The MHT resulted in a low sensitivity
(78%) and speciﬁcity (57%). The CDT could be very useful in
daily practice to provide fast and reliable detection of KPC and
MBL carbapenemases among P. aeruginosa isolates.
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Detection of carbapenemase producers in the clinical labora-
tory is of major importance for the determination of appro-
priate therapeutic schemes and the implementation of
infection control measures [1,2]. Several inhibitor-based tests
have been developed for the detection of carbapenemase
producers. Recently, a combination disk test (CDT) for the
detection of metallo-b-lactamase (MBLs) and KPC in Entero-
bacteriaceae with the use of meropenem disks supplemented
with 3-aminophenylboronic acid (APB), dipicolinic acid (DPA)
or cloxacillin was described [3]. Typically, KPC-producing
Enterobacteriaceae showed an increased meropenem inhibition
zone (ZI) in the presence of APB, a class A carbapenemase
and class C b-lactamase inhibitor. Unlike KPC-producing iso-
lates, those with combined AmpC overproduction and porin
loss gave positive results in the APB test, but also showed clox-
acillin (a class C b-lactamase inhibitor) synergy. MBL producers
showed an increased meropenem zone diameter in the pres-
ence of DPA, a class B b-lactamase inhibitor [3]. The Modiﬁed
Hodge test (MHT) has been widely used for carbapenemase
screening in Enterobacteriaceae [4], but it has not been further
explored in Pseudomonas aeruginosa. The aim of this study was
to determine whether the CDT and the MHT would be able
to discriminate between various carbapenemase-producing
P. aeruginosa isolates and carbapenemase non-producers.
A panel of P. aeruginosa isolates (n = 149) were included.
The carbapenemases represented were (n): KPC (36), VIM-2
(16), SPM-1 (8), VIM-11 (5), IMP-13 (5), and IMP-16 (4)
(Pasteran et al., 49th ICAAC, 2009, Abstract 1003). The
resistance mechanisms among carbapenemase non-producers
were (n): wild type (6), narrow-spectrum-b-lactamases (2),
extended-spectrum b-lactamases (7), cephalosporinase over-
production (7), efﬂux overproduction (15) and dual mecha-
nisms (efﬂux plus cephalosporinase overproduction, 38). The
isolates were from clinical sources. All strains corresponded
to different pulsed-ﬁeld gel electrophoresis types [5], with
the exception of KPC producers, which were divided into
two pulsed-ﬁeld gel electrophoresis types. KPC producers
belonged to two multilocus sequence types (STs): ST654 and
ST162 (http://pubmlst.org/paeruginosa/). b-Lactamases were
characterized by PCR and DNA sequencing [6,7]. AmpC-
type cephalosporinase production was determined with spec-
trophotometric assays [8,9]. Efﬂux estimation was performed
as described previously [10]. The CDT was performed with
freshly prepared disks [3]. The MHT was performed with
Escherichia coli ATCC 25922 as the indicator organism, as
described previously [4].
First, we evaluated the performance of carbapenemase
screening by using meropenem ZIs. Meropenem ranges (in
mm) were 6–9, 6–23 and 6–34 for KPC producers, MBL
producers and carbapenemase non-producers, respectively.
Thus, all carbapenemase producers had a ZI £23 mm, coinci-
dent with a non-susceptible result as deﬁned by EUCAST
criteria (http://www.eucast.org/clinical_breakpoints/).
Subsequently, we tested the CDT by using the b-lactam-
ase inhibitor concentration and the cut-off values reported
for Enterobacteriaceae: 600 lg of APB per disk (Sigma, St.
Louis, MO, USA), 750 lg of cloxacillin per disk (Hangzkou
BM Chemical, Hangzkou, China) and 1000 lg of DPA per
disk (Sigma). For APB, an increment ‡4 mm in zone diameter
around disks containing the inhibitor, as compared with the
disk with meropenem alone, was used as the cut-off; for
DPA and cloxacillin, an increment ‡5 mm was considered to
be a positive result [3]. When tested in P. aeruginosa, APB
synergy detected all but one of the isolates producing KPC
(average increments of 9 mm). None of these strains showed
cloxacillin synergy (no increments observed), and thus were
properly classiﬁed as KPC producers (Table 1). Cephalospo-
rinase overproducers were also positive in the APB test.
Unexpectedly, none of these strains showed cloxacillin syn-
ergy under the conditions described for Enterobacteriaceae
(average increments of 2 mm), and were therefore incor-
rectly classiﬁed as KPC producers (speciﬁcity of 40%). To
reduce the number of false-positive results, we tested disks
with 1500 lg of cloxacillin: 85% of cephalosporinase over-
producers still had average increments of 3 mm, and were
overestimated as KPC producers (speciﬁcity of 49%). Subse-
TABLE 1. Sensitivities and speciﬁcities of dipicolinic acid (DPA), 3-aminophenylboronic acid (APB) and cloxacillin in the com-
bination disk test for detecting various b-lactamases
Test(s) Resistant mechanism sought by test Sensitivity (%) Speciﬁcity (%)
APB-positive plus cloxacillin-negative KPC 97 97 (98)a
DPA-positive MBL 97 81
APB-negative or APB-positive plus cloxacillin-positive Carbapenemase non-producer 97 (98)a 97
Modiﬁed Hodge test Carbapenemase producer 78 57
aCorrected values with the inclusion of strains with halos of meropenem £23 mm (a screening breakpoint deﬁned in this study).
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quently, we evaluated disks with 3000 lg of cloxacillin, and
obtained average increments of 4 mm. Thus, we decided to
use a less exigent cut-off value of ‡3 mm for a positive result
with the 3000-lg cloxacillin disk. With these conditions, all
but two cephalosporinase overproducers were classiﬁed as
true producers of this mechanism (speciﬁcity of 97%;
Table 1). With the test conditions described for Enterobacte-
riaceae, DPA detected all MBL producers except for one
VIM-11 producer (average increments of 9 mm). About 17
MBL non-producers (distributed as follows: cephalosporinase
overproducers (n = 3), efﬂux overproducers (n = 3), dual
mechanisms (n = 8), and extended-spectrum b-lactamase
producers (GES-1 (n = 2) and OXA-31 (n = 1)) were also
positive with the DPA test (Table 1).
With the MHT, a high proportion of indeterminate results
(inhibition of the growth of the indicator strain produced by
the test isolate) was observed (22% and 43% of carbapenem-
ase producers and non-producers, respectively). Thus, the
sensitivity and speciﬁcity were 78% and 57%, respectively
(Table 1).
We present here for the ﬁrst time a method with high
sensitivity and speciﬁcity for the detection of KPC-producing
P. aeruginosa isolates. The proposed test is an improvement
on the CDT recommended for Enterobacteriaceae [3]. The
APB and DPA concentrations and cut-off values for screening
in P. aeruginosa were coincident with those used for screen-
ing in Enterobacteriaceae. However, the cloxacillin concentra-
tion (750 lg per disk) and the respective cut-off value
recommended for screening in Enterobacteriaceae overesti-
mated the presence of KPC producers among P. aeruginosa
isolates at a rate of 60%. Higher concentrations of cloxacillin
(3000 lg per disk) and a lower cut-off value were required,
probably because of the greater impermeability of the
P. aeruginosa outer membrane.
On the basis of our results, we propose a preliminary
scheme for phenotypic carbapenemase screening in P. aeru-
ginosa (Fig. 1). Screening starts with the routine meropenem
results: a ZI £23 mm (non-susceptible by EUCAST) categori-
cally selects isolates suspected of producing carbapenemases.
The actual number of P. aeruginosa strains that will be
included with this cut-off value in any given laboratory will
depend upon the local epidemiology: in Europe, it is esti-
mated to be 14% of the strains (http://www.eucast.org/mic_
distributions), and in Argentina 31% (WHONET-Argentina
Network). Subsequently, the CDT should be performed.
With this protocol, laboratories will detect >95% of carbape-
nemase producers. Finally, the assumptions of carbapene-
mase production made on the basis of the CDT should be
conﬁrmed by molecular methods. The MHT was not
included, because of the unacceptable performance; indeter-
minate results occurred at a rate ten times higher than that
for Enterobacteriaceae [7].
One limitation of the study is that KPC producers belong
to a reduced number of clones. However, it should be noted
that ST564, the most prevalent clone included in this study,
has been reported in Singapore, where it is also endemic and
has been associated with IMP-type MBLs (http://pubmlst.org/
paeruginosa/), and it has also been reported in Sweden as a
VIM producer, indicating that this is a successful, worldwide,
multiresistant clone with the ability to acquire relevant carba-
penemases [11]. Therefore, we believe that is highly likely
that, at least, ST654 will have an important role in the global
dissemination of KPC in P. aeruginosa, and the CDT has
shown an excellent performance among strains belonging to
this ST. Another limitation is that isolates producing both
MBL and KPC could emerge simultaneously in the near future,
and could pose another challenge to this protocol. As pro-
posed for Enterobacteriaceae, such isolates could probably be
identiﬁed with the addition of both DPA and APB to merope-
nem disks (Casals et al., 21st ECCMID, 2011, Abstract 697).
In conclusion, we propose a phenotypic screening strategy
for identiﬁcation of carbapenemases among P. aeruginosa iso-
FIG. 1. Preliminary protocol for carbapenemase screening among
Pseudomonas aeruginosa isolates. APB, 3-aminophenylboronic acid;
AST, antimicrobial susceptibility test; CDT, combination disk test;
DPA, dipicolinic acid; MBL, metallo-b-lactamase. The algorithm
required a meropenem disk (10 lg) and meropenem disks supple-
mented with 600 lg of APB per disk, 1000 lg of DPA per disk and
3000 lg of cloxacillin per disk.
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lates, based on the meropenem susceptibility test result and
the use of meropenem disks supplemented with APB, cloxa-
cillin or DPA. These tests will enable routine laboratories to
identify, with high conﬁdence levels, those P. aeruginosa iso-
lates suspected of producing either KPC or MBL carbapene-
mases.
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Abstract
Fifty-six isolates of serotype 1 were identiﬁed during a 20-year
prospective study (1989–2008), including all children with cul-
ture-proven invasive pneumococcal disease (IPD) admitted to a
children’s hospital in Barcelona. Forty-eight of them (85.7%)
were in children aged >2 years. Complicated pneumonia
(n = 28) and non-complicated pneumonia (n = 20) were the
main clinical presentations. The frequency of serotype 1 IPD
increased from 1999–2003 to 2004–2008: 1.2 to 4.4 episodes/
100 000 children (p <0.001). The ST306 clone were identiﬁed in
70.4% of isolates. As IPD caused by serotype 1 is mainly
detected in older children, a vaccination programme for children
>2 years should be considered.
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